Medicare Enrolled
Dr. Haskell Kirkpatrick, MD
Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kirkpatrick from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kirkpatrick?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kirkpatrick
Dr. Haskell Kirkpatrick is a medical oncology specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kirkpatrick performed 158,235 Medicare services across 4,784 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kirkpatrick received a total of $1,333 from 27 pharmaceutical and/or device companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kirkpatrick is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 4% volume in TX
$1,333 industry payments
Medicare Practice Summary
Medicare Utilization ↗158,235
Medicare services
Top 4% in TX for medical oncology
4,784
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~8,328 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia | 26,190 | $2 | $20 |
| Anti-nausea injection (fosaprepitant) | 21,450 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 20,600 | $43 | $137 |
| Iron sucrose injection (Venofer) | 18,200 | $0 | $2 |
| Filgrastim injection (Zarxio) for white blood cells | 10,320 | $0 | $2 |
| Paclitaxel chemotherapy injection | 10,096 | $0 | $8 |
| Daratumumab injection (Darzalex) | 8,280 | $38 | $127 |
| Oxaliplatin chemotherapy injection | 8,200 | $0 | $33 |
| Iron infusion (Feraheme) | 6,120 | $0 | $5 |
| Dexamethasone injection (steroid) | 2,827 | $0 | $1 |
| Immune globulin infusion (Octagam) | 2,360 | $34 | $235 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,790 | $1 | $114 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,766 | $24 | $155 |
| Blood draw (venipuncture) | 1,668 | $8 | $20 |
| Injection, granisetron hydrochloride, 100 mcg | 1,630 | $0 | $24 |
| Complete blood count (CBC) with differential | 1,478 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,433 | $10 | $64 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,370 | $20 | $181 |
| Denosumab injection (Prolia/Xgeva) | 1,320 | $18 | $66 |
| Injection, bortezomib, 0.1 mg | 1,260 | $4 | $116 |
| Contrast dye for imaging (iodine-based) | 1,135 | $0 | $3 |
| Office visit, established patient (30-39 min) | 679 | $95 | $368 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 589 | $23 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 561 | $103 | $707 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 528 | $80 | $1,348 |
| Injection, carboplatin, 50 mg | 376 | $2 | $300 |
| Injection, fluorouracil, 500 mg | 322 | $2 | $13 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 318 | $3 | $373 |
| Injection, zoledronic acid, 1 mg | 314 | $6 | $431 |
| Injection, potassium chloride, per 2 meq | 305 | $0 | $1 |
| Drug injection, under skin or into muscle | 273 | $11 | $96 |
| Office visit, established patient (20-29 min) | 261 | $60 | $250 |
| Injection, magnesium sulfate, per 500 mg | 236 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 224 | $50 | $313 |
| Injection of additional new drug or substance into vein | 209 | $12 | $108 |
| Infusion, normal saline solution , 1000 cc | 200 | $2 | $19 |
| Lactate dehydrogenase (enzyme) level | 185 | $6 | $31 |
| Injection, diphenhydramine hcl, up to 50 mg | 166 | $1 | $7 |
| Microscopic examination for white blood cells with manual cell count | 160 | $4 | $22 |
| Complete blood count (CBC), automated | 160 | $6 | $34 |
| Administration of additional new drug or substance into vein, 1 hour or less | 148 | $49 | $344 |
| Administration of chemotherapy into vein, each additional hour | 139 | $22 | $161 |
| Ferritin level test (iron stores) | 138 | $13 | $60 |
| Iron level test | 137 | $6 | $27 |
| Iron binding capacity test | 137 | $9 | $35 |
| Office visit, established patient, complex (40-54 min) | 133 | $136 | $496 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 132 | $20 | $128 |
| Carcinoembryonic antigen (cea) protein level | 122 | $19 | $99 |
| Hospital follow-up visit, moderate complexity | 120 | $62 | $247 |
| Injection, cisplatin, powder or solution, 10 mg | 113 | $1 | $94 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 111 | $56 | $211 |
| Measurement of immunoglobulin light chains | 108 | $17 | $60 |
| Unclassified drugs | 94 | $1 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 93 | $15 | $100 |
| Infusion into a vein for hydration, 31-60 minutes | 76 | $26 | $256 |
| Immunoglobulin level test | 69 | $9 | $56 |
| Basic metabolic blood panel | 66 | $8 | $49 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 61 | $26 | $145 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 59 | $1 | $19 |
| PSA test (prostate cancer screening) | 53 | $18 | $94 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 52 | $71 | $70 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 48 | $135 | $3,675 |
| Infusion into a vein for hydration, each additional hour | 44 | $10 | $75 |
| New patient office visit (30-44 min) | 42 | $84 | $372 |
| Application of on-body injector for under skin injection | 41 | $15 | $96 |
| Administration of additional new drug or substance into vein using push technique | 37 | $44 | $289 |
| New patient office visit (45-59 min) | 37 | $117 | $565 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 37 | $132 | $500 |
| Injection, lorazepam, 2 mg | 31 | $1 | $3 |
| Irrigation of implanted venous access drug delivery device | 30 | $20 | $114 |
| Hospital follow-up visit, low complexity | 28 | $39 | $135 |
| Drawing of blood for a medical problem | 27 | $72 | $264 |
| Urinalysis with microscopic exam | 18 | $3 | $28 |
| Red blood count automated, with additional calculations | 18 | $5 | $26 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 17 | $1,187 | $4,802 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 17 | $90 | $657 |
| New patient office visit, complex (60-74 min) | 16 | $163 | $709 |
| Initial hospital admission, moderate complexity | 14 | $102 | $470 |
| Ct scan of chest with contrast | 13 | $66 | $821 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
6.2% high complexity
88.8% medium
5.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,333
Total received (2018-2024)
Avg $190/year across 7 years
Bottom 33% in TX for medical oncology
27
Companies
54
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,321 (99.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12 (0.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$702
2023
$268
2022
$143
2021
$48
2020
$37
2019
$80
2018
$55
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Kite Pharma, Inc.
$206
Incyte Corporation
$124
Janssen Biotech, Inc.
$93
AstraZeneca Pharmaceuticals LP
$83
Genentech USA, Inc.
$69
GlaxoSmithKline, LLC.
$66
INTUITIVE SURGICAL, INC.
$64
Merck Sharp & Dohme LLC
$64
Tempus AI, Inc
$58
Stemline Therapeutics Inc.
$49
Takeda Pharmaceuticals U.S.A., Inc.
$47
ABBVIE INC.
$46
Novartis Pharmaceuticals Corporation
$39
E.R. Squibb & Sons, L.L.C.
$35
Bayer Healthcare Pharmaceuticals Inc.
$34
Gilead Sciences, Inc.
$32
Celgene Corporation
$29
Ipsen Biopharmaceuticals, Inc
$28
Aveo Pharmaceuticals, Inc.
$25
GENZYME CORPORATION
$24
PFIZER INC.
$23
PUMA BIOTECHNOLOGY, INC.
$19
Blueprint Medicines Corporation
$17
Astellas Pharma US Inc
$17
ARRAY BIOPHARMA INC
$16
Pharmacyclics LLC, An AbbVie Company
$14
Dova Pharmaceuticals
$12
Top 3 companies account for 31.8% of total payments
Associated products mentioned in payments ›
ALUNBRIG · Alecensa · DARZALEX · Da Vinci Surgical System · Doptelet · ELIQUIS · ELITEK · ELZONRIS · ENHERTU · FOTIVDA · FRUZAQLA · GAVRETO · IMBRUVICA · IMFINZI · Imbruvica · JAKAFI · KEYTRUDA · MONJUVI · NERLYNX · Nubeqa · OJJAARA · ONUREG · OPDIVO · Onivyde · Orserdu · PIQRAY · PROMACTA · RYBREVANT · SPRYCEL · Tecentriq · VENCLEXTA · XALKORI · Xtandi · Yescarta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $1 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
91
Per 100K population
3.5
County median income
$74,149
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL DALLAS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kirkpatrick is a mixed practice specialist, with above-average Medicare volume (top 4% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kirkpatrick experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Kirkpatrick performed 26,190 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kirkpatrick receive payments from pharmaceutical companies?
Yes. Dr. Kirkpatrick received a total of $1,333 from 27 companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kirkpatrick's costs compare to other medical oncologists in Dallas?
Dr. Kirkpatrick's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kirkpatrick) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Dallas
Browse medical oncologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Kite Pharma, Inc. Payments to Doctors
See all physicians who received payments from Kite Pharma, Inc.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology